AI Terminal
DIACEUTICS PLC
Report Publication Announcement • Sep 9, 2024
7596_rns_2024-09-09_dc069565-c79f-437c-980d-1f907e1b81bb.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 2990D
Diaceutics PLC
09 September 2024
Diaceutics - Notice of Results & Presentations
Belfast and London, 9 September 2024 - Diaceutics PLC ( AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, will announce its unaudited results for the half year ended 30 June 2024 on Tuesday, 17 September 2024.
Analyst Presentation:
A webinar presentation for analysts and investors will be held at 1330 BST (0830 ET) on Tuesday, 17 September 2024 . Those wishing to attend can register using the following link:
Investor Meet Presentation:
A webinar presentation for investors will be held via the Investor Meet platform at 1630 BST (1130 ET) on Tuesday, 17 September 2024 . The presentation is open to all existing and potential shareholders and registration can be completed via the following link:
https://www.investormeetcompany.com/diaceutics-plc/register-investor
Questions can be submitted pre-event via your Investor Meet Company dashboard up until 0900 BST the day before the meeting or at any time during the live presentation. Investors who already follow Diaceutics on the Investor Meet Company platform will automatically be invited.
Enquiries:
| Diaceutics PLC | |
| Ryan Keeling, Chief Executive Officer Nick Roberts, Chief Financial Officer |
Tel: +44 (0)28 9040 6500 [email protected] |
| Canaccord Genuity Limited (Nomad & Broker) | Tel: +44 (0)20 7523 8000 |
| Simon Bridges, Andrew Potts, Harry Rees | |
| Alma Strategic Communications | Tel: +44(0)20 3405 0205 |
| Caroline Forde, Kinvara Verdon | [email protected] |
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NORUPUGCBUPCGCQ